Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases
Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases
复制标题
DOI：
10.1093/annonc/mdp334
复制
发表时间：
2010-03-01
影响因子：
50.5
通讯作者：
Papotti, M.
中科院分区：
文献类型：
--
作者：
Righi, L.;Volante, M.;Papotti, M.
背景：肺神经内分泌肿瘤(Nets)，尤其是临床侵袭性类癌和大细胞神经内分泌癌(LCNECs)的治疗尚不规范，有关生长抑素受体(SSTR)表达或生长抑素类似物治疗指南的数据仍存在争议。材料和方法：应用免疫组织化学方法对218例肺Net[24例转移性典型类癌(TCS)，73例非典型类癌(ACS)，60例LCNEC和61例手术切除的小细胞肺癌(SCNECs)]2A型和3型SSTR的组织分布与临床病理参数、预后、组织分布进行了研究结果：SSTR分布不均，从低级别到高级别呈明显递减趋势。2A型SSTR在转移性TCS中的表达显著高于ACS和临床良性TCS。结论：免疫组织化学检测SSTR，特别是低/中级别肿瘤，可能有助于临床上采用生长抑素类似物对临床侵袭性肺网络进行诊断和治疗。
Background: The management of pulmonary neuroendocrine tumours (NETs), with special reference to clinically aggressive carcinoids and large-cell neuroendocrine carcinomas (LCNECs), is poorly standardised and data about somatostatin receptor (SSTR) expression or therapeutic guidelines for somatostatin analogue administration are still debated.Materials and methods: A series of 218 lung NETs [24 metastatic typical carcinoids (TCs), 73 atypical carcinoids (ACs), 60 LCNECs and 61 surgically resected small-cell lung carcinomas] were investigated for SSTR types 2A and 3 tissue distribution using immunohistochemistry, in correlation with clinicopathologic parameters, outcome, scintigraphy and treatment.Results: SSTRs were heterogeneously distributed with a significant progressive decrease from low-to high-grade forms. SSTR type 2A was strikingly overexpressed in metastatic TCs as compared with ACs and clinically benign TCs. SSTR tissue immunolocalization correlated with octreotide scintigraphy in 20 of 28 cases.Conclusion: The immunohistochemical determination of SSTRs, with special reference to low-grade/intermediate-grade tumours, may assist the clinical approach with somatostatin analogue-based diagnostic and therapeutic procedures in clinically aggressive pulmonary NETs.